Super-TDU | 99.78%(HPLC) | In Stock

Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.

Super-TDU Chemical Structure

CAS: 1599441-71-0

Selleck's Super-TDU has been cited by 10 publications

Purity & Quality Control

Batch: Purity: 99.78%

99.78

Super-TDU Related Products

Related Products	CA3 (CIL56) YAP-TEAD Inhibitor 1 (Peptide 17) TED-347	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Bioactive Compound Library-Ⅱ Highly Selective Inhibitor Library	Click to Expand

Choose Selective YAP Inhibitors

Biological Activity

Description

Super-TDU is an inhibitory peptide targeting YAP-TEADs interaction.

Targets

YAP/TEAD interaction ^[1]

In vitro
In vitro	Super-TDU reduced endogenous interaction between YAP and TEADs. It inhibits cell viability and colony formation of GC cell lines MGC-803, BGC-823, and HGC27, but not MKN-45. Moreover, the Super-TDU downregulated expression of YAP-TEADs target genes CTGF, CYR61, and CDX2. Super-TDU significantly inhibited growth of HeLa, MGC-803, HCT116, A549, and MCF-7 cells, but only marginally inhibited growth of Jurkat and Raji cells, indicating a selectivity of the Super-TDU in inhibiting tumor cell growth. Super-TDU may specifically target tumor cells with an elevated YAP/VGLL4 ratio^[1].
Cell Research	Cell lines	HCT116 and SW480 cells
	Concentrations	0-320 ng/ml
	Incubation Time	72 h
	Method	Cells are transfected with the indicated plasmids. An ATP-based cell viability assay is used for detecting cell proliferation. The ATP content is measured. Briefly, 100 μl of assay reagent is added to the wells, and mixed for 2 min at room temperature. After 10 min, intracellular ATP content is measured using a multilabel luminescence counter. Cell viability is calculated.

In Vivo
In vivo	Super-TDU has the potential in treating gastric cancer by directly targeting YAP-TEADs, and importantly, unlike the conventional drug compound 5-FU, its antitumor activity tends to be specific toward tumors with an elevated ratio of YAP to VGLL4^[1].
Animal Research	Animal Models	BALB/cA nu/nu mice
	Dosages	50 or 500 μg/kg
	Administration	tail vein injection

References
[1] Jiao S, et al. Cancer Cell. 2014, 25(2):166-80. [2] Jiao S, et al. Nat Commun. 2017, 8:14058.

References

Chemical Information & Solubility

Molecular Weight	5279.94	Formula	C₂₃₇H₃₇₀N₆₆O₆₉S
CAS No.	1599441-71-0	SDF	Download Super-TDU SDF
Smiles	CCC(C)C(C(=O)NCC(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)N2CCCC2C(=O)C(=O)C(CCC(=O)N)NNC(C(C)O)C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)NC(CCSC)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)N4CCCC4C(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(=O)NC(CCCCN)C(=O)N7CCCC7C(=O)N8CCCC8C(=O)NC(CCC(=O)O)C(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC9=CNC1=CC=CC=C19)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NNC(CO)C=O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Water : 100 mg/mL

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):